Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

ABSTRACT:

Aims

To assess real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) among patients with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib monotherapy.

Patients & methods

In this US-nationwide, electronic health record-derived, deidentified database study, eligible patients with EOC initiated 1LM niraparib monotherapy (1 January 2017-1 December 2022) following first-line platinum-based chemotherapy. Median rwPFS and rwTTNT were estimated with Kaplan-Meier methodology overall and in a homologous recombination-deficient (HRd) subgroup (further stratified as BRCA wild-type [BRCAwt] or BRCA-mutated [BRCAm]).

Results

Observed median rwPFS was 11.4 (95% CI, 10.1-12.7) months overall (

SUBMITTER: Salani R 

PROVIDER: S-EPMC11792861 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature